PVLA • NASDAQ
Palvella Therapeutics, Inc.
$120.41
Stock Details
| Market Cap | 1,425,231,761 |
|---|---|
| Day Change | 32.57 (37.08%) |
| Volume | 1,180,898 |
| Avg Volume | 275,590 |
| Price Range | 18.225-127.69 |
Overview
| Country | US |
|---|---|
| Sector | Healthcare |
| Industry | Biotechnology |
| Exchange | NASDAQ |
Company Profile
Palvella Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel therapies to treat patients serious and rare genetic skin diseases. Its lead product candidate is QTORIN 3.9% rapamycin anhydrous gel (QTORIN rapamycin) that is in Phase 3 clinical trial for the treatment of microcystic lymphatic malformations, as well as in Phase 2 clinical trial to treat cutaneous venous malformations. It also develops QTORIN rapamycin for the treatment of other mTOR-driven skin diseases. The company is based in Wayne, Pennsylvania.
Financial Overview
| 52 Week High | 114.69 |
|---|---|
| 52 Week High Date | 2025-12-22 |
| 52 Week Low | 18.05 |
| 52 Week Low Date | 2025-02-21 |
| 10D Avg Trading Vol | 0.28551 |
| YTD Price Return Daily | -16.0791 |
| MTD Price Return Daily | 14.5391 |
Cash Flow
| TTM/Share | |
|---|---|
| Annual/Share | -0.9844 |
| Quarterly/Share | -2.0517 |
Price-to-Earnings
| Annual Ratio | 7.3296 |
|---|---|
| Quarterly Ratio | 6.4912 |
| TTM |
Revenue
| 3Y Growth | 13.44 |
|---|---|
| 5Y Growth | 8.03 |
| Annual/Share | |
| TTM/Share | 0.7638 |
| 5Y Share Growth | -2.8 |
Earnings Per Share
| Annual | -7.6233 |
|---|---|
| 3Y Growth | |
| 5Y Growth | |
| Quarterly YOY Growth |
Price-to-Book
| Ratio | 26.8786 |
|---|---|
| Annual Ratio | 2.5541 |
| TTM | 17.9239 |